GlassScriptPhysician profile
David John Moylan
NPI 1447245899
$1,401.81
in general payments reported to CMS, 2019-2025
22 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $30.61 · 2021: $161 · 2022: $132 · 2023: $233 · 2024: $208 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $300.55 | 2019-2025 | Keytruda |
| Insmed, INC. | $135.13 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $122.85 | 2021-2023 | Libtayo |
| Astellas Pharma US INC | $114.98 | 2019 | |
| Exelixis INC. | $97.68 | 2021-2025 | Cabometyx |
| Gilead Sciences, INC. | $90.00 | 2023 | Trodelvy |
| Janssen Biotech, INC. | $73.42 | 2019-2024 | Erleada, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $55.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.69 | 2020-2023 | |
| Kite Pharma, INC. | $27.99 | 2019 | |
| Myriad Genetic Laboratories, INC. | $27.98 | 2021 | |
| Eisai INC. | $24.88 | 2022 | |
| Genentech USA, INC. | $22.26 | 2024 | Perjeta, Itovebi, Phesgo |
| Lexicon Pharmaceuticals, INC. | $22.21 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $19.53 | 2023 | Illuccix |
| Karyopharm Therapeutics INC. | $18.74 | 2024 | Xpovio |
| Secura Bio, INC. | $18.07 | 2019 | |
| Philips North America LLC | $17.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.98 | 2022 | |
| Daiichi Sankyo INC. | $16.06 | 2022 | |
| Rigel Pharmaceuticals, INC. | $14.64 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Moylan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.